AB SCIENCE News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

17.12.24	AB Science provides a summary of the webcast held on December 16, 2024 (GlobeNewswire)
11.12.24	AB Science will host a live webcast on Monday December 16, 2024, from 5.30pm to 6.30pm CET (GlobeNewswire)
28.10.24	AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease (GlobeNewswire)
17.10.24	AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS (GlobeNewswire)
10.10.24	AB Science: Revenues for the first half of 2024 and update on AB Science’s activities (GlobeNewswire)
30.09.24	AB Science announces a slight delay in the publication of its 2024 half-year financial report (GlobeNewswire)
26.09.24	AB Science provides an update on the microtubule program AB8939 and in particular the ability of AB8939 to generate response on MECOM rearrangement (GlobeNewswire)
23.09.24	AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024 (GlobeNewswire)
08.07.24	AB Science announces positive results of its Phase 2 study evaluating masitinib in Covid-19 (GlobeNewswire)
28.06.24	AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS (GlobeNewswire)
31.05.24	AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS (GlobeNewswire)
29.05.24	AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS (GlobeNewswire)
15.05.24	AB Science reports its revenues for the year 2023 and provides an update on its activities (GlobeNewswire)
13.05.24	AB Science announces issuance of a European patent for masitinib in the treatment of severe mastocytosis with protection until 2036 (GlobeNewswire)
02.05.24	AB Science : The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science (GlobeNewswire)
30.04.24	AB Science announces a slight delay in the publication of its 2023 annual financial report (GlobeNewswire)
03.04.24	AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS (GlobeNewswire)
13.03.24	AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease (GlobeNewswire)
07.03.24	AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development (GlobeNewswire)
06.03.24	AB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the Company (GlobeNewswire)
01.03.24	AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET (GlobeNewswire)
29.02.24	AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET (GlobeNewswire)
26.02.24	AB Science announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) for masitinib in ALS (GlobeNewswire)
26.01.24	AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines Agency (GlobeNewswire)
15.01.24	AB Science receives notice of allowance for European patent covering masitinib until 2036 in the treatment of mastocytosis (GlobeNewswire)
28.11.23	AB Science will host a live webcast on Thursday November 30, 2023, from 3pm to 4pm CET, to present the masitinib development program in sickle cell disease (GlobeNewswire)
27.11.23	AB Science: The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)” (GlobeNewswire)
29.09.23	AB Science today reports its revenues for the first half of 2023 and provides an update on its activities (GlobeNewswire)
18.09.23	AB Science provides an update on the EMA timetable for examination of the masitinib marketing authorization application in ALS (GlobeNewswire)
26.06.23	AB Science receives Notice of Allowance for European patent covering masitinib in the treatment of metastatic castrate refractory prostate cancer (mCRPC) (GlobeNewswire)
01.06.23	AB Science announces issuance of a Canadian patent for masitinib in the treatment of ALS with protection until 2037 (GlobeNewswire)
17.05.23	AB Science summarizes key messages from its participation to a panel discussion at the 2023 ALS Drug Development Summit (GlobeNewswire)
09.05.23	AB Science announces that Health Canada has resumed its review of the New Drug Submission for masitinib in amyotrophic lateral sclerosis, following issuance of a screening acceptance letter (GlobeNewswire)
28.04.23	AB Science reports its revenues for the year 2022 and provides an update on its activities (GlobeNewswire)
27.04.23	AB Science - Summary of the presentation on masitinib in ALS delivered at 2023 AAN Annual Meeting (GlobeNewswire)
24.04.23	AB Science announces the success of its capital increase by private placement for an amount of 15 million euros (GlobeNewswire)
21.04.23	AB Science announces the implementation of a new strategy and the launch of a capital increase (GlobeNewswire)
18.04.23	AB Science announces masitinib patent granted in Japan for the treatment of amyotrophic lateral sclerosis, strengthening the Company’s intellectual property position until 2037 (GlobeNewswire)
12.04.23	AB Science: Results of masitinib in ALS selected for a scientific platform presentation at the AAN 2023, including long-term survival analysis and a new analysis of patient population with no complete (GlobeNewswire)
04.04.23	AB Science announces that it has submitted its response to the day 120 questions in the EMA regulatory review of masitinib in amyotrophic lateral sclerosis and clarifies the new timeline for respondin (GlobeNewswire)
15.03.23	AB Science will host a live webcast on its microtubule destabilizer agents (MDA) platform on Thursday March 16, 2023, from 6pm to 7pm CET (GlobeNewswire)
13.03.23	AB Science reports a first complete bone marrow response in a relapsed refractory acute myeloid leukemia patient from the very low dose arm of its AB8939 Phase I/II clinical trial (AB18001) (GlobeNewswire)
28.02.23	AB Science announced the publication of the masitinib pivotal phase 3 clinical trial in Alzheimer’s Disease in the journal Alzheimer's Research & Therapy (GlobeNewswire)
21.12.12	AB Science: FINANCIAL CALENDAR (Businesswire)
05.11.12	Skuldtech and AB Science Announce the Identification of New Predictive Markers for Pancreatic Cancer Survival Associated with Masitinib Treatment (Businesswire)
03.11.12	Skuldtech and AB Science announce the identification of new predictive markers for pancreatic cancer survival associated with masitinib treatment (Businesswire)
30.10.12	AB Science reports phase 3 study results of masitinib in combination with Gemzar® for treatment of pancreatic cancer. (Businesswire)
16.10.12	AB Science confirms the filing for the Marketing Authorization Application to the European Medicines Agency of Masitinib in the treatment of Pancreatic Cancer (Businesswire)
11.10.12	CORRECTING AND REPLACING: AB Science: Turnover up 41% compared to 2011 third quarter (Businesswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V